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Abstract
Backgrounds: Autism is a family of developmental disorders of unknown origin. The disorder is characterized by
behavioral, developmental, neuropathological and sensory abnormalities, and is usually diagnosed between the
ages of 2 and 10 with peak prevalence rates observed in children aged 5-8 years. Recently, there has been
heightened interest in the role of plasma free fatty acids (FA) in the pathology of neurological disorders. The aim
of this study is to compare plasma fatty acid profiles of Saudi autistic patients with those of age-matching control
subjects in an attempt to clarify the role of FA in the etiology of autism.
Methods: 26 autistic patients together with 26-age-matching controls were enrolled in the present study. Methyl
esters of FA were extracted with hexane, and the fatty acid composition of the extract was analyzed on a gas
chromatography.
Results: The obtained data proved that fatty acids are altered in the plasma of autistic patients, specifically
showing an increase in most of the saturated fatty acids except for propionic acid, and a decrease in most of
polyunsaturated fatty acids. The altered fatty acid profile was discussed in relation to oxidative stress, mitochondrial
dysfunction and the high lead (Pb) concentration previously reported in Saudi autistic patients. Statistical analysis
of the obtained data shows that most of the measured fatty acids were significantly different in autistic patients
compared to age -matching controls.
Conclusions: Receiver Operating Characteristic (ROC) curve analysis shows satisfactory values of area under the
curve (AUC) which could reflect the high degree of specificity and sensitivity of the altered fatty acids as
biomarkers in autistic patients from Saudi Arabia.
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Introduction
Autism is a developmental disorder characterized by
impaired communication and social behavioral features,
as well as displays of stereotypical behavior, present in
the first 3 years of life [1]. Diagnosis of autism is beha-
vior based, and a single behavior or group of behaviors
is able to distinguish autism from other developmental
disorders [2]. The pathogenesis of autism is uncertain,
but is thought to involve an interaction between multi-
ple susceptibility genes and/or epigenetic effects and/or
environmental factors [3-5].
Lipids are heterogeneous molecules that serve many
roles, from providing cell structure to energy storage for
cell signaling. The brain is one of the most lipid-
enriched tissues in the human body. Infants’ brains are
small and undeveloped at birth and must incorporate
fatty acids and cholesterol from circulation to develop
properly [6]. Docosahexanoic acid (DHA) in particular
is found in high abundance in the phospho- lipids of
the brain contributing to membrane structure and func-
tion, eicosanoid signaling, and gene expression modula-
tion [7,8]. DHA also plays a role in inhibition of
neuronal apoptosis and in regulating neuronal excitabil-
ity through GABA receptors [9,10]. Furthermore, there
is evidence that developing brains obtain fatty acids
transported through the blood, especially DHA [11].
Thus, examining the concentrations and compositions
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important.
Mitochondrial fatty acid oxidation (FAO) deficiencies
usually present in the neonate or toddler with hypoketo-
tic hypoglycaemia, metabolic acidosis, mitochondrial
dysfunction, hyperammonemia, muscle weakness, cardi-
omyopathy, seizures, psychomotor delay, developmental
regression, behavioral disorders and attention deficit dis-
order [12-15]. Neonatal presentations are usually severe
with poor prognosis and include cardiac arrhythmia and
sudden death [16], however in mild phenotypes there
may be an initial period of normal development and
function before decompensation in association with
metabolic stress or immune activation, such as fasting,
illness or vaccination [17]. With the exception of cardiac
involvement and sudden death, all of the metabolic and
developmental abnormalities listed above may occur in
autism, and the onset of autism may also be regressive
following a period of initially normal infant develop-
ment. This information initiates our interest to examine
the plasma fatty acid profiles in autistic patients com-
pared to age-matched control. This may explain their
diagnostic and mechanistic roles in a developmental dis-
order such as autism.
Material and methods
Subjects
The study protocol followed the ethical guidelines of the
most recent Declaration of Helsinki (Edinburgh, 2000).
All subjects enrolled in the study (26 autistic patients
and 26 age-matched controls) had written informed
consent provided by their parents and assented to parti-
cipate if developmentally able. They were enrolled
through the ART Center (Autism Research & Treatment
Center) clinic. The ART Center clinic sample population
consisted of children diagnosed on the autism spectrum
(ASD). The diagnosis of ASD was confirmed in all sub-
jects using the Autism Diagnostic Interview-Revised
( A D I - R )a n dt h eA u t i s mD i a g n o s t i cO b s e r v a t i o nS c h e -
dule (ADOS) and 3DI (Developmental, dimensional
diagnostic interview). The ages of all autistic children
who participated were between the ages of 4 and 12
years old. All were simplex cases. All are negative for
fragile x gene study. The control group recruited from
well baby clinic at king Khaled university hospital with
mean age 4-11 years old. Subjects were excluded from
the investigation if they had organic aciduria, dys-
morphic features, or diagnosis of Fragile X or other ser-
ious neurological (e.g., seizures), psychiatric (e.g., bipolar
disorder) or known medical conditions. All participants
were screened via parental interview for current and
past physical illness. Children with known endocrine,
cardiovascular, pulmonary, liver, kidney or other medical
disease were excluded from the study. None of the
recruited autistic patients were on special diets or alter-
native treatments.
Samples collection
Blood samples were collected in the morning following
at least 10 hour period of fasting. Plasma was collected
using standard clinical practices and stored at -80°C
until thawed for analysis.
Fatty acid profiling
Plasma (200 μl) lipids were extracted in the presence of
internal standards and FA methylated using 3N methano-
lic HCL in sealed vials under nitrogen and incubated at
100C for 45 min. The methyl esters of free fatty acids
were extracted with hexane, and the fatty acid composition
of the extract was analyzed on a gas chromatograph
(Helwlett- Packard 5890 series II plus, HP analytical
Direct, Wilmington, DE), equipped with a flame ionization
detector and a 30 m × 0.25 mm × 0.25 μm capillary col-
umn(Omegawax 250# 2-4136, Supelco). The helium gas
flow rate was 1.2 ml/min, with a split/flow ratio of 50:1.
Oven temperature was held at 205°C. The injector and
detector temperatures were 260 and 262°C, respectively.
Two internal standards, C15:0 and C23:0, were added dur-
ing analysis. Fatty acids were identified via comparison of
retention times with authentic standards [18].
Statistical analysis
An SPSS computer program was used. Results were
expressed as mean ± S.D. and all statistical comparisons
were made by means of independent t-Test with P ≤
0.001 was considered significant. Reciever Operating
Characteristics analysis (ROC) was performed. Area
under the curve, cutoff values together with degree of
specificity and sensitivity were calculated. ROC curves
are constructed by plotting the false positive rate (i.e.
100-specificity) against the true positive rate (i.e. sensi-
tivity). These have been widely accepted as standard
tools for evaluating the performance of diagnostic tests.
The AUC is an overall summary of diagnostic accuracy,
incorporating both components of accuracy, i.e., sensi-
tivity and specificity, into a single measure. The AUC
has been widely used as a quantitative index of the per-
formance of a biomarker in a variety of applied fields; it
is a simple and convenient overall measure of diagnostic
test [19,20].
Results
Results are presented in tables 1, 2, 3 & 4 and figures 1,
2, &3. Fatty acids concentrations were calculated as
mmoles/L plasma. Values are expressed as mean ± S.D,
P value between all controls and all autistic subjects is
reported for each fatty acid and illustrated as a star
when P < 0.001.
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Page 2 of 8Table 1 Mean ± S.D of plasma levels of acetic, valeric, hexanoic and stearidonic saturated fatty acids in autistic
patients compared to age- matching controls
Fatty acid Group N Mean ± S.D. Percentage change P value
Acetic Control 26 0.558 ± 0.082 100.00 0.000
Autistic 26 0.972 ± 0.247 174.14
Valeric Control 26 0.100 ± 0.015 100.00 0.000
Autistic 26 0.510 ± 0.229 509.27
Hexanoic Control 26 0.597 ± 0.478 100.00 0.000
Autistic 26 1.442 ± 0.349 241.65
Stearidonic Control 26 0.363 ± 0.122 100.00 0.009
Autistic 26 0.455 ± 0.120 125.17
This table describes the independent t-test between the control and autistic groups regarding levels of acetic, valeric, hexanoic and stearidonic acids expressed
in mmol/L plasma. Significant level at p < 0.001
Table 2 Mean ± S.D of saturated, mono and polyunsaturated fatty acids in plasma of autistic patients compared to
controls
Fatty acid Group N Mean ± S.D. Percentage change P value
Propionic Control 26 1.674 ± 0.441 100.00 0.000
Autistic 26 0.874 ± 0.249 52.23
Butyric Control 26 0.738 ± 0.211 100.00 0.028
Autistic 26 0.587 ± 0.267 79.54
Caprylic Control 26 2.250 ± 0.481 100.00 0.000
Autistic 26 1.109 ± 0.281 49.31
Decanoic Control 26 1.954 ± 0.750 100.00 0.000
Autistic 26 0.759 ± 0.182 38.81
Lauric Control 26 1.903 ± 0.574 100.00 0.000
Autistic 26 0.808 ± 0.160 42.45
Palmitic Control 26 1.905 ± 0.537 100.00 0.037
Autistic 26 1.631 ± 0.372 85.62
Stearic Control 26 1.219 ± 0.315 100.00 0.000
Autistic 26 0.687 ± 0.281 56.36
Arachidic Control 26 0.673 ± 0.174 100.00 0.000
Autistic 26 0.425 ± 0.222 63.10
a-Linolenic Control 26 0.354 ± 0.119 100.00 0.045
Autistic 26 0.299 ± 0.067 84.35
Eicosapentaenoic Control 26 0.328 ± 0.112 100.00 0.245
Autistic 22 0.284 ± 0.145 86.64
Docosahexaenoic Control 26 0.754 ± 0.340 100.00 0.000
Autistic 22 0.380 ± 0.097 50.40
Linoleic Control 26 0.359 ± 0.162 100.00 0.023
Autistic 26 0.220 ± 0.255 61.35
g-Linolenic Control 26 0.716 ± 0.323 100.00 0.000
Autistic 20 0.162 ± 0.101 22.59
Arachidonic Control 26 0.574 ± 0.202 100.00 0.000
Autistic 20 0.120 ± 0.040 20.89
Oleic Control 26 1.212 ± 0.518 100.00 0.000
Autistic 26 0.225 ± 0.064 18.55
Elaidic Control 26 0.234 ± 0.080 100.00 0.000
Autistic 26 0.122 ± 0.099 52.28
This table describes the independent t-test between the control and autistic groups specified saturated, mono and polyunsaturated fatty acids. Fatty acids are
expressed in mmol/L plasma. Significant level at p < 0.001
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Page 3 of 8Table 1 and figure 1 demonstrate the elevated plasma
levels in autistic patients of the following saturated fatty
acids: acetic, valeric, hexanoic and stearidonic. While
stearidonic acid shows the least percentage increase
(25%), valeric acid shows highest plasma levels in autis-
tic patients compared to controls (409.27%). Acetic and
hexanoic acids gave 74.14 and 41.65% increase
respectively.
On the other hand, Table 2 demonstrates the
reduced levels of different saturated, mono or polyun-
saturated fatty acids in autistic patients when com-
pared to control subjects. Figure 2 shows different
percentage decrease of saturated (propionic, butyric,
caprylic, decanoic, lauric, palmitic and stearic) together
with mono (oleic) and polyunsaturated fatty acids.
Oleic, arachidonic, g-linolenic, decanoic, caprilic and
propionic were the most significantly impaired levels
recorded percentage decreases of 81.45, 79.11, 77.41,
61.14, 50.6 and 47.77%, respectively.
ROC curves are presented in figure 3 (a-k). Area
under the curve, cutoff values together with degree of
specificity and sensitivity are presented in table 3 and
4 respectively. It could be easily noticed that autistic
patients have remarkably different fatty acid profiles
compared to controls. Most of the measured fatty
acids recorded high values of specificity and
sensitivity.
Discussion
B i o m a r k e r ss h o u l di d e a l l yb eq u a n t i t a t i v eb i o l o g i c a l
measures with an accurate indication of a specific
mechanism and ideally are not invasive. Identifying bio-
markers will almost certainly lead to a better under-
standing of the pathogenesis required to design the
most effective treatments of autism.
The present study recorded high significant alterations
in the fatty acid profiles of autistic patients compared to
age-matching controls. Table 1 demonstrates levels of
certain saturated fatty acids in both groups. It could be
easily seen that short chain fatty acids represented by
acetic, valeric, hexanoic and stearidonic acids were sig-
nificantly higher in autistic patients compared to control
(table 1 and figure 1). The significantly higher level of
acetic acid could be easily related to the gastrointestinal
inflammation as one of the most common clinical pre-
sentation of autism. It is well known that acetic acid
induced colitis is a well -established model [21-23]
whereby acetate ions cause massive intracellular
Table 3 Roc analysis - related data of valeric, hexanoic and stearidonic saturated fatty acids
Fatty acid Area under the curve Best Cutoff value Sensitivity % Specificity %
Acetic 0.985 0.684 92.3% 92.3%
Valeric 1.000 0.196 100.0% 100.0%
Hexanoic 0.916 1.009 92.3% 88.5%
Stearidonic 0.734 0.344 80.8% 65.4%
Table 4 Roc analysis - related data of specified saturated, mono and polyunsaturated fatty acids
Fatty acid Area under the curve Best Cutoff value Sensitivity % Specificity %
Propionic 0.963 1.279 92.3% 84.6%
Butyric 0.655 0.689 65.4% 50.0%
Caprylic 0.972 1.617 100.0% 92.3%
Decanoic 0.996 1.197 100.0% 92.3%
Lauric 1.000 1.214 100.0% 100.0%
Palmitic 0.631 1.874 69.2% 46.2%
Stearic 0.897 0.975 84.6% 84.6%
Arachidic 0.823 0.462 76.9% 92.3%
a-Linolenic 0.611 0.325 69.2% 50.0%
Eicosapentaenoic 0.617 0.283 54.5% 57.7%
Docosahexaenoic 0.876 0.427 77.3% 84.6%
Linoleic 0.791 0.162 76.9% 100.0%
Y-Linolenic 0.996 0.338 100.0% 96.2%
Arachidonic 1.000 0.271 100.0% 100.0%
Oleic 1.000 0.463 100.0% 100.0%
Elaidic 0.831 0.213 80.8% 76.9%
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inflammatory response [24].
The most remarkable elevation in fatty acid level in
the present study was observed in valeric acid. The
extremely high level of valeric acid ( 409.27% increase)
could be related to the increase of a-keto b-methyl vale-
ric acid (KMV) derivative previously reported as an anti-
oxidant highly effective in neutralizing H2O2 oxidative
stress [25]. The authors reported that tissue accumula-
tion and high urinary excretion of KMV occurred in
maple syrup urine disease (MSUD) which shows neuro-
logical dysfunction. They assessed the effect of KMV on
the activities of the mitochondrial respiratory chain
complexes in cerebral cortex from young rats in an
attempt to elucidate the biochemical defect responsible
for the inhibition of aerobic metabolism (lower CO2 for-
mation) and activation of anaerobic glycolysis (increased
lactate release). They recorded that KMV inhibited com-
plex I-III of the respiratory chain and significantly sti-
mulated lactate production by around 20-30%.
Therefore, it may be concluded that KMV could alter
the energy metabolism in brain cortex. In addition, the
high level of plasma valeric acid observed in the present
study could be easily explained and correlated to the
H2O2 oxidative stress, impaired energy metabolism, and
elevated plasma lactate previously recorded in Saudi
autistic patients [26-29].
The recent work performed by MacFabe et al. (2007)
[30] concerns the role of a panel of gut-borne factors in
autism spectrum disorder through using a novel rodent
model. The transport of propionate and butyrate across
the blood brain barrier was previously ascertained
[31-34]. These authors demonstrated that intracerebro-
ventricular infusions of short chain fatty acids produced
behavioral (hyperactive, preservative, social impair-
ments), electrophysiological (seizure, caudate spiking),
biochemical (increased oxidative stress, reduced glu-
tathione, lipids) and neuropathological (innate neuroin-
flammation) changes in adult rats consistent with those
seen in autism. References regarding the further devel-
opment of this model from the behavioral to biochem-
ical levels will further support this study findings and
reduce the plausible argument that the lipid alterations
a r em e r e l ya ne p i p h e n o m e n ac a u s e db yap o o rd i e ta n d
have nothing to do with autism pathophysiology per se.
14Cp r o p i o n a t ea n d
14C hydroxybutyrate were found to
cross the blood-brain barrier with brain uptake indexes
of 43.53 and 7.10%, respectively. Transport of both of
these substrates was saturable, with the values of trans-
port Km being 2.03 and 6.54 mM, respectively. These
differences in brain uptake indexes and transport Km
values could be used to explain the obtained lower
plasma propionate than butyrate recorded in the present
s t u d yi na u t i s t i cp a t i e n t sc o m p a r e dt oh e a l t h ya g e -
matching controls. Since the lower the Km, the higher
the affinity of the transporters for the substrates, so an
uptake index of 43.53% and a km value of 2.03 are
enough to facilitate the penetration of propionate to the
brain cell.
The observed results could confirm the previous work
of MacFabe et al. (2007) [30] concerning the role of
PPA in the etiopathology of autism and the possibility
to use this short chain fatty acid to induce autism like
behaviors and biochemical changes in animal model.
Lower level of PPA in plasma of autistic patients could
reflect the remarkable higher rate of uptake with brain.
There is growing interest in the roles of n-3 PUFA
docosahexaenoic acid (DHA) and precursor eicosapen-
taenoic acid (EPA) in brain structure, function and men-
tal health [35-37]. The longest chain n-3 DHA is the
most abundant PUFA in brain membrane phospholipids
indicative of its role in membrane fluidity and associated
metabolic and neural activities. DHA is particularly con-
centrated at neural synapses, sites of neurotransmitter
signalling. Omega-6 PUFA AA is also abundant in the
brain reflecting a key role for brain structure and
Figure 1 Percentage change in valeric, hexanoic and
stearidonic acids of autistic patients (N = 26) compared to
control (N = 26).
Figure 2 Percentage decrease of saturated and unsaturated
fatty acids in plasma of autistic patients (N = 26) compared to
control (N = 26), presented as the first bar to the left showing
100% value.
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and n-3 DHA precursor EPA are thought to be impor-
tant for brain function via eicosanoid synthesis. EPA
may be particularly important for production of eicosa-
noids with anti-inflammatory, anti-thrombotic, and
vasodilatory properties [37].
PUFA have been proclaimed as critical for intellectual
growth and development in the developing neonatal/
infant brain and in early childhood [38]. Given that
brain development, particularly executive functioning
(EF), continues throughout childhood [39,40], PUFA
could also play an important role in cognitive function
in older children. In addition, PUFA have been specifi-
cally associated with dopamine activity in the frontal
lobes of the brain [41], which may impact directly on
EF, and has been associated with Attention Deficit
Hyperactivity Disorder (ADHD) [42].
Infants’ brains are small and undeveloped at birth and
must incorporate fatty acids and cholesterol from circu-
lation to develop properly [43]. DHA plays a role in
inhibition of neuronal apoptosis and in regulating neu-
ronal excitability through GABA receptors [9,10].
Furthermore, there is evidence that developing brains
obtain fatty acids transported through the blood, espe-
cially DHA [11].
The present investigation also indicated significantly
lower levels of most PUFA (table 2 and figure 2), with
exception of EPA which recorded non-significant lower
concentration. This is in good agreement with the pre-
vious reports of Vancassel et al (2001) [44] who
recorded decreased levels of the essential fatty acid
DHA with normal levels of its omega-3 precursor in
autism. Decreased DHA together with mild to moderate
increases in lactate were observed in long chain FAO
disorders [45]. Based on these observations, the lower
level of DHA observed in the present study could be
easily correlated to the previously reported increase of
lactic acid in Saudi autistic patients [46].
In addition, lower level of AA recorded in the present
work could find support through considering the work
of Wiest et al. (2009) who attributed the impaired
inflammatory responses seen in autistic patients to the
diminished AA level in their plasma [47].
Diets rich in saturated fats may increase brain uptake
of intact free fatty acids from the plasma through the
blood brain barrier (BBB) [48], the BBB is not a barrier
for fatty acids [49]. Patil and Chan (2005) study the role
of FFAs in causing hyperphosphorylation of tau in pri-
mary rat cortical neurons [50]. The observed FFA-astro-
cyte-induced hyperphosphorylation of tau was reduced
by co-treatment of neurons with 10mM N-acetyl
cysteine (NAC), an antioxidant suggesting a central role
of astroglia-mediated oxidative stress in the FFA-
induced hyperphosphorylation of tau in neurons. Several
Figure 3 Roc curves demonstrate AUC, specificity and sensitivity values of different fatty acids as biomarkers of autism.
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sue Pb and oxidative stress biomarkers and fatty acid
composition [51-54]. The impaired fatty acid profile
recorded in the present study could be easily supporting
the previous reports which demonstrate high plasma Pb,
elevated lipid peroxidation and low GSH levels in Saudi
autistic patients compared to control [46].
It is proposed that saturated fatty acids (SFA) induce
BBB dysfunction and delivery of toxic substances from
blood- to-brain [55]. Moreover, Morgan (2009) [56] sug-
gests that the underlying toxicity of SFA is a conse-
quence of disturbances in protein processing and
endoplasmic reticulum dysfunction, for example apopto-
tic induction. The present recognition of short chain
fatty acids as biomarkers in Saudi autistic children could
be supported through considering lipid-related biomar-
kers recorded in other neurological diseases. Miyake et
al (2010) [54] observed positive relationship between
cholesterol intake and the risk of Parkinson’s disease
(PD) but he recorded unaltered SFA levels in PD
patients which is incompatible with the hypercholestero-
lemic effect of these acids. In addition, an emerging
body of evidence is consistent with the hypothesis that
dietary fats influence Alzheimer’s disease (AD) risk, but
less clear is the mechanisms by which this occurs. Accu-
mulating evidence that dietary fats, specifically, chronic
ingestion of saturated fats significantly influence cere-
brovascular integrity and as a consequence altered amy-
loid beta (Ab) kinetics across the BBB [55]. Regarding
the role of saturated fatty acids in the etiology of autism,
impaired mitochondrial FAO, elevated plasma very long
chain saturated fatty acids (VLCFAs) was recorded as
putative causal factors in the biochemistry, neuropathol-
ogy, and gender bias in autism. This study is the first
study which highlights the contribution of short chain
fatty acids in the etiology of autism.
ROC curves are constructed by plotting the false
positive rate (i.e. 100-specificity) against the true posi-
tive rate (i.e. sensitivity). These have been widely
accepted as standard tools for evaluating the perfor-
mance of diagnostic tests. The AUC is an overall sum-
mary of diagnostic accuracy, incorporating both
components of accuracy, i.e., sensitivity and specificity,
into a single measure. The AUC has been widely used
as a quantitative index of the performance of a bio-
marker in a variety of applied fields; it is a simple and
convenient overall measure of diagnostic test [19,20].
According to the presented ROC related data (tables 3
and 4, figure 3), it could be easily concluded that
impaired fatty acid profiles could be used as diagnostic
biomarkers in Saudi autistic patients. Most of the mea-
sured fatty acids show a satisfactory level of specificity
and sensitivity.
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